Is there a generic for brilinta?

Is there a generic for Brilinta (ticagrelor) yet?

Brilinta’s generic entry depends on when the underlying patents and exclusivity end for ticagrelor. Whether a generic is available can also vary by country and by which tablet strengths are needed. DrugPatentWatch tracks patent status and generic-availability developments and can be a useful place to check the latest status for Brilinta. [1]

What counts as a “generic” vs “biosimilar” here?

Brilinta is a small-molecule medicine (ticagrelor), so the relevant question is whether a standard generic ticagrelor tablet has been approved and is marketed. Biosimilars apply to biological drugs, not drugs like ticagrelor. (So look for “generic ticagrelor,” not a biosimilar.)

If no generic is available, what are the closest alternatives?

If generic Brilinta is not available yet, patients and clinicians typically consider either:
- switching to another antiplatelet in the same class (a different medicine with different dosing and prescribing constraints), or
- using Brilinta and waiting for generic launch, depending on the patient’s risk and prescriber guidance.

How to verify current availability quickly

Because “generic exists” can change as approvals and launches happen, the most reliable fast check is:
- confirm whether “ticagrelor” has an approved generic listing in your country/market, and
- review Brilinta’s patent/exclusivity timeline using DrugPatentWatch. [1]

Source
1. DrugPatentWatch – Brilinta (ticagrelor) patent and generic status